Sign in

CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464600503
Phone
617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4 Planned sale Chief Financial Officer sold 40,000 shares at an average $30.19 ($1,207,742)
  2. 4 Planned sale Co-Chief Executive Officer sold 100,000 shares at an average $29.84 ($2,983,838)
  3. 4 Planned sale Co-Chief Executive Officer sold 100,000 shares at an average $29.84 ($2,983,678)
  4. 4 Planned sale Director sold 30,000 shares at $27.70 ($830,904)
  5. 4 Open-market sale Chief Medical Officer sold 10,028 shares at an average $32.40 ($324,868)
  6. 4 Open-market sale Chief Financial Officer sold 10,810 shares at an average $32.36 ($349,821)
  7. 4 Open-market sale Chief Legal Officer sold 9,536 shares at an average $32.46 ($309,506)
  8. 4 Open-market sale Co-Chief Executive Officer sold 30,464 shares at an average $32.18 ($980,263)
  9. 4 Open-market sale Co-Chief Executive Officer sold 30,464 shares at an average $32.19 ($980,504)
  10. 4 Option exercise Director acquired 50,000 shares (option exercise)
  11. 4 Grant or award Chief Financial Officer acquired 22,807 shares (grant or award)
  12. 4 Grant or award Co-Chief Executive Officer acquired 60,039 shares (grant or award)
  13. 4 Grant or award Chief Legal Officer acquired 21,284 shares (grant or award)
  14. 4 Grant or award Chief Medical Officer acquired 22,807 shares (grant or award)
  15. 4 Grant or award Co-Chief Executive Officer acquired 60,039 shares (grant or award)
  16. 4 Planned sale Chief Legal Officer sold 30,000 shares at an average $17.96 ($538,868)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 1 of 11 · 207 filings